Mesoblast Ltd's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 199 out of 391 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 34.67.In the medium term, the stock price is expected to trend down.
Media Coverage
The current financial score of Mesoblast Ltd is 5.67, ranking 336 out of 391 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 3.16M, representing a year-over-year decrease of 6.85%, while its net profit experienced a year-over-year decrease of 47.31%.
Key Metrics
The current valuation score of Mesoblast Ltd is 7.41, ranking 121 out of 391 in the Biotechnology & Medical Research industry. Its current P/E ratio is -16.98, which is -100.00% below the recent high of 0.00 and -45.96% above the recent low of -24.78.
The current earnings forecast score of Mesoblast Ltd is 8.00, ranking 163 out of 391 in the Biotechnology & Medical Research industry. The average price target is 35.00, with a high of 35.00 and a low of 35.00.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
No price momentum score is currently available for Mesoblast Ltd. The Biotechnology & Medical Research industry's average is 6.32.
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
The current institutional shareholding score of Mesoblast Ltd is 3.00, ranking 195 out of 391 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 3.00%, representing a quarter-over-quarter increase of 10.71%. The largest institutional shareholder is Steven Cohen, holding a total of 38.19K shares, representing 0.03% of shares outstanding, with 3600.00% increase in holdings.
The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Mesoblast Ltd is 5.03, ranking 57 out of 391 in the Biotechnology & Medical Research industry. The company's beta value is 2.23. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.
